Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Last Days of the Early Bird Pricings for Biologics World China 2012

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
Keep up to date with China’s changing biopharma landscape by registering for Biologics World China 2012.

In the last few weeks three major joint ventures have been announced between international pharma’s and Chinese pharma’s. Merck & Co. will be working with Simcere, Pfizer is partnering with Hisun while AstraZeneca will be working with WuXi Appatec to develop and commercialize MEDI5117, a biologic for rheumatoid arthritis.

Giving us an insight into both big pharma and China will be AstraZeneca’s head of the China Biologics Innovation Center Jaiwen Han at Biologics World China 2012.

Biologics World China 2012  will be held on 5-7 November 2012 at Radisson Blu Hotel Pudong Century Park in Shanghai, China.

Organizations that are already confirmed attending include:
•    3S Bio
•    Acertus Pharma LLC
•    Bayer Pharma
•    BD Bioscience
•    BeiGene
•    Beijing Mab-Works
•    Beijing Triprime Genetic Engineering Co. Ltd.
•    Boehringer Ingelheim
•    BravoBio
•    Bristol-Myers Squibb
•    China Biologic Products
•    Chinese-Taipei Biotechnology Service Association
•    Citibank
•    Gan&Lee Pharmaceuticals
•    Genor BioPharma
•    Huabei Organization New Drug Development Company
•    HUYA Bioscience International
•    Innovent Biologics
•    Jiangsu Simcere Pharmaceutical R&D Co. Ltd
•    June He Law Offices
•    King Lai
•    Merck & Co.
•    Merck Millipore
Be heard, be seen by China's biologics industry!

Limited sponsorship and exhibition opportunities

If you have technologies, services or consulting expertise to offer to China’s Biopharma industry, it's your opportunity to act now!

Sartorius Stedim Biotech, Merck Millipore, Boehringer Ingelheim, TAP Biosystems, King Lai and BD Bioscience are already on board to showcase their capabilities at Biologics World China 2012.

Don't be the one to miss out! This unique and targeted biologics platform will be your one stop solution to reach out to the booming Chinese biopharma market!

80% of the exhibition and sponsorship opportunities have been sold and only very few showcase opportunities left!


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IMAPAC to Bring Together Over 150 Leading Industry Players
IMAPAC’s 3rd Biologics Korea gathering from 22-24 April 2014 in Seoul, Korea.
Wednesday, February 19, 2014
Regional Health Authorities to Meet and Discuss Russia’s 2020 Vision
Government aims for 50% of sold drugs to be manufactured in Russia by 2020.
Thursday, September 05, 2013
Top Biologic Industry Leaders to Convene at Biologics World Korea 2013
Bringing together biologics drug innovators and bioprocess professionals from all around the world to discuss strategies in biosimilar and biobetter development, as well as cutting-edge advances in bioprocessing and bioanalytics.
Friday, December 07, 2012
The Movement of China's Burgeoning Biologics Market
Facilitate innovation and manufacturing of affordable and high quality biologic drugs and vaccines in China.
Friday, August 24, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!